Nanoviricides, Inc. (NNVC)

NanoViricides, Inc. operates in the pharmaceutical industry, specifically in the development of antiviral drugs using its proprietary nanoviricide platform technology. The company is a clinical stage entity with no approved drugs, customers, or revenues to date. The industry is characterized by the challenge of viruses rapidly evolving to evade traditional vaccines, antibodies, and small chemical drugs. The company's technology is designed to address this by mimicking host cell receptors, making it difficult for viruses to escape. The market for antiviral therapeutics is substantial, with the RSV therapeutics market estimated at $1.8 billion in 2022 and expected to reach $8.73 billion by 2031, and the Influenza and Bird Flu market estimated at $4.6 billion in 2024, growing to $5.9 billion in three years.

The company's competitive positioning is based on its unique nanoviricide platform, which it believes offers advantages over traditional antiviral approaches. The company states that NV-387 is the only drug candidate it is aware of with a broad spectrum of activity against multiple virus families, including RNA and DNA viruses, and that it has demonstrated safety and tolerability in humans. The company's drugs are designed to be host-mimetic and direct-acting, not requiring a healthy immune system, which it believes is superior to vaccines and antibodies. The company also highlights its fully integrated facilities, including cGMP-compliant manufacturing, which it believes de-risks its development programs and enables rapid advancement. The company has not commercialized any product and faces competition from existing antiviral drugs such as Remdesivir, Ribavirin, Cidofovir, and Brincidofovir, which it notes have dose-limiting toxicities.

NanoViricides generates revenue through licensing and out-licensing agreements, as well as potential milestone payments and royalties. The company has out-licensed its drug candidates NV-CoV-2 and NV-CoV-2-R to Karveer Meditech Pvt. Ltd. (KMPL) for development and commercialization in India, under which KMPL will pay the company a royalty of 70% of net sales. The company also has exclusive licenses from TheraCour Pharma, Inc. for various viral disease fields, and upon commercialization, the company will pay TheraCour 15% of net sales. The company's business model is based on developing drug candidates into regulatory approvals and partnering or sub-licensing for commercialization. The company has no recurring revenue streams and has financed its operations through equity-based financing, including registered direct offerings and at-the-market offerings.

The company's lead drug candidate is NV-387, a broad-spectrum antiviral designed to mimic sulfated proteoglycans (S-PG), which are used by over 90% of human pathogenic viruses as attachment receptors. NV-387 has completed a Phase Ia/Ib clinical trial for safety and tolerability, with no adverse events reported. The company is planning or conducting Phase II clinical trials for NV-387 as a treatment for Mpox, Ebola, Measles, and viral acute and severe acute respiratory infections (ARI/SARI). The drug is formulated as oral gummies, oral syrup, and an injectable solution for various routes of administration. The company also has NV-HHV-1, a drug candidate for herpesviruses, which has completed IND-enabling studies as a skin cream for Shingles. Additionally, the company is developing NV-HIV-1 for HIV, and other candidates for various viruses, including Dengue and Ebola.

The company has several other drug candidates in its pipeline, including NV-CoV-2-R, which contains remdesivir encapsulated within the nanoviricide micelles, and NV-387-Rp and NV-387-Ribvp, which contain modified forms of remdesivir and a prodrug of ribavirin, respectively. These Modality 3 drugs are designed to block both the extracellular virus and intracellular replication, potentially enabling cures for non-latency viruses. The company has also developed a co-formulation of NV-387 and tecovirimat, called NV-387-m-T, which showed significantly better survival improvement in animal models than either drug alone. The company's pipeline includes over forty different viral disease indications, with more than ten drug candidates that could be rapidly moved into the clinical stage.

During fiscal year 2026, the company achieved significant operational milestones. The company received regulatory approval from ACOREP in the DRC for its Phase II clinical trial of NV-387 Oral Gummies for the treatment of Mpox, and subsequently for the treatment of Ebola. The company shipped the drug product for both trials to the DRC in June 2026. The company also improved its manufacturing process, approximately doubling the production scale of NV-387 to a batch size of approximately 6kg, with a 10kg scale feasible. The company raised equity-based funding through registered direct offerings and an ATM offering, selling 1,264,988 shares at an average price of approximately $1.56 per share, and entering into a registered direct offering on November 10, 2025, with net proceeds of approximately $5,404,000, and another on May 15, 2026, with net proceeds of approximately $1,703,000. The company also obtained a $3 million line of credit from Dr. Anil Diwan, which had not been drawn upon as of June 30, 2026.

The company's financial performance for fiscal year 2026 reflects its clinical stage status, with no revenues generated. The company had approximately $2.8 million cash in hand as of June 30, 2026. Cash used in operating activities was approximately $7.7 million for the year ended June 30, 2026, a decrease of approximately $800,000 compared to $8.5 million in the prior year. The company has long-term assets of $6.4 million post-depreciation and amortization, representing its facilities. The company believes it has sufficient financing to close the Phase Ia/Ib clinical trial and execute the Phase II clinical trials for Mpox and Ebola, but anticipates needing additional financing to complete data analysis and report submission.

The company's outlook is focused on achieving clinical milestones, including the submission of the final clinical study report for NV-387, the initiation and completion of Phase II clinical trials for Mpox and Ebola, and the filing of clinical trial applications for Measles and viral ARI/SARI indications. The company also anticipates filing for Orphan Drug Designation for NV-387 for the treatment of Mpox, Smallpox, and Measles, and filing pre-IND applications for Smallpox and Ebola.

A major growth vector is the expansion of NV-387 into multiple indications, including Mpox, Ebola, Measles, and viral respiratory infections. The company believes that positive data from the Phase II Mpox and Ebola trials could lead to non-dilutive US Government funding for further development, particularly for Smallpox as a biodefense application. The company also sees potential for NV-387 to become the world's first empiric antiviral treatment for respiratory infections, akin to broad-spectrum antibiotics. The company plans to pursue a Phase II clinical trial for Measles under a US FDA IND, which could qualify for a Priority Review Voucher (PRV), recently sold for about $200-220 million. The company also plans to develop NV-387 for pediatric RSV treatment, a market expected to reach $8.73 billion by 2031.

Another growth vector is the development of the company's other drug candidates, including NV-HHV-1 for herpesviruses and NV-HIV-1 for HIV. The company plans to re-engage its HerpeCide and HIV programs when sufficient resources become available. The company also plans to develop Modality 3 drugs, such as NV-387-Rp and NV-387-Ribvp, which have shown strong effectiveness against Coronaviruses and RSV in animal models and could potentially provide cures for non-latency viruses. The company is also seeking partnerships and out-licensing opportunities, having retained Aagami, Inc. to develop pharma collaborations primarily with Indian and Japanese big pharma companies.

The company's margin and cost outlook is focused on minimizing development costs through its in-house manufacturing capabilities and cost-effective regulatory strategies. The company believes that developing NV-387 in the orphan and rare infectious diseases space first will be substantially less expensive than its commercially important drug programs. The company also plans to use a 'basket-type' clinical trial for viral respiratory infections to save on costs of conducting multiple clinical trials. The company's cash used in operating activities decreased by approximately $800,000 in fiscal year 2026, primarily due to a decrease in investor outreach expenses.

The company's operational outlook includes continuing to use its own cGMP-compliant facilities for manufacturing drug substances and products. The company has the capability to produce sufficient drugs for about 1,000 patients in a single batch, which is anticipated to be sufficient for its Phase II clinical trials and potentially for commercialization of NV-387 for pediatric RSV. The company plans to either employ an external CMO for injectable drug products or develop in-house injectables manufacturing capabilities. The company also plans to bring some regulatory affairs capabilities in-house in the near future to speed up regulatory processes.

The company's capital allocation plans include continuing to finance its drug development programs using equity-based financing, including registered direct offerings and ATM offerings. The company has an ATM sales agreement with D. Boral Capital LLC for up to $50 million in aggregate offering price, and a new At Market Issuance Sales Agreement entered into on July 17, 2026. The company also has a $3 million line of credit from Dr. Anil Diwan, which bears interest at 12% and matures on December 31, 2027. The company plans to seek non-dilutive grants and contracts funding for its drug candidates, particularly for NV-387 for Smallpox under the US FDA Animal Rule.

The company faces headwinds related to the execution of its clinical trials in resource-poor settings, such as the remote site for the Mpox trial in the Sankuru province, which has led to significant obstacles in site preparation. The company also faces regulatory and macro factors, including the need to obtain approvals from local agencies like ACOREP and the US FDA. The company's ability to raise additional funds is uncertain, and it may not be able to obtain financing on terms acceptable to it. The company also faces the risk that its drug candidates may not be successfully partnered or obtain non-dilutive funding.

The company's growth is constrained by its limited resources, which have led to the reprioritization of its development plans. The company's progress to clinic is limited by its resources, and it plans to advance other drug candidates as financial resources become available. The company also faces the risk that its clinical trials may not be successful, and that the data may not support regulatory approvals. The company's ability to achieve its milestones is dependent on its ability to raise additional funds, which is not guaranteed.

Management's message emphasizes the substantial accomplishments in fiscal year 2026, including the expansion of NV-387's potential indications and the initiation of Phase II clinical trials for Mpox and Ebola. The tone is optimistic, highlighting the broad-spectrum antiviral activity of NV-387 and its potential to revolutionize the treatment of viral infections. Management emphasizes a cost-effective regulatory strategy, focusing on orphan and rare infectious diseases first, and the potential for non-dilutive funding and early revenues. Key strategic priorities include advancing the Phase II clinical trials for Mpox and Ebola, developing a 'basket-type' clinical trial for viral respiratory infections, and seeking partnerships and non-dilutive funding. Management also highlights the company's fully integrated facilities and manufacturing capabilities as a key differentiator. The company believes it has sufficient financing to execute the Phase II trials but anticipates needing additional financing for data analysis and report submission.

The company is a clinical stage entity with no revenues, and its financial performance is characterized by cash used in operations. For the fiscal year ended June 30, 2026, the company had approximately $2.8 million cash in hand ¹. Cash used in operating activities was approximately $7.7 million ² for the year ended June 30, 2026, compared to $8.5 million ³ in the prior year ended June 30, 2025, a decrease of approximately $800,000 ⁴. The company has long-term assets of $6.4 million ⁵ post-depreciation and amortization, representing its facilities. The company also has a $3 million ⁶ line of credit from Dr. Anil Diwan, which had not been drawn upon as of June 30, 2026 ⁷. The company raised net proceeds of approximately $1,909,000 ⁸ from an ATM offering, $5,404,000 ⁹ from a registered direct offering on November 10, 2025, and $1,703,000 ¹⁰ from a registered direct offering on May 15, 2026. The company's net loss is not explicitly stated in the filing, but the cash used in operations provides an indication of its burn rate. The company's financial position is typical for a clinical stage biopharmaceutical company with no product revenues.

The company faces significant risks related to its clinical stage status, with no approved drugs, customers, or revenues to date, and may never achieve revenues or profitable operations. The company's drug candidates are in early stages of development, and there is no guarantee that they will receive regulatory approvals. The company's Phase II clinical trials for Mpox and Ebola are being conducted in the DRC, which presents logistical and operational challenges, including the need to prepare remote clinical trial sites. The company's ability to raise additional financing is uncertain, and it may not be able to obtain funds on terms acceptable to it. The company's intellectual property is licensed from TheraCour, and the licenses could revert only in the case of a default by NanoViricides, effectively only in the event of insolvency. The company's drug candidates may not be successfully partnered or obtain non-dilutive funding, and the company may need to continue financing its efforts using equity-based financing, which could be dilutive to shareholders. The company's manufacturing capabilities, while a strength, also present risks if the facilities are not maintained or if the company is unable to scale up production. The company's reliance on external parties for regulatory development and clinical trials introduces risks related to the performance of these parties. The company's drug candidates may face competition from existing and future antiviral drugs, and the company's technology may not be accepted by the market. The company's ability to achieve its milestones is dependent on its ability to raise additional funds, which is not guaranteed.